Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIC-114 in EGFR- or HER2-altered advanced solid tumors
2024-512264-66-00Phase 2Authorised
- Sponsor
- ORIC Pharmaceuticals
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label trial of enozertinib in Nonhematologic neoplasms and cancer (3 arms), sponsored by ORIC Pharmaceuticals. Primary endpoints: Provisional RP2Ds and/or MTD of ORIC-114, Optimal ORIC-114 RP2D and 3 more. Planned start Sep 2024; status: authorised.
02
Drugs
enozertinib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2024-512264-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512264-66-00.